Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study

Authors

Hiroyuki Kurakami (ORCID: https://orcid.org/0000-0002-1025-1861)
Takashi Tsuboi (ORCID: https://orcid.org/0000-0001-5042-3181)
Liqin Ge (ORCID: https://orcid.org/0000-0001-9622-3732)
Masaru Yokoe
Hiroyuki Mochizuki (ORCID: https://orcid.org/0000-0001-9377-3368)
Osamu Kano (ORCID: https://orcid.org/0000-0003-3748-3694)
Kanako Asai (ORCID: https://orcid.org/0009-0005-7464-8912)
Dai Matsuse
Yasuyoshi Kimura (ORCID: https://orcid.org/0000-0001-9147-8058)
H. Kato
Shigeru Sakamoto (ORCID: https://orcid.org/0000-0002-1818-2194)
Toru Koda
Masahiko TOMIYAMA
Koji Iwasaki
Yoshitaka Nagai
Noriyuki Matsukawa

Institutions

Osaka Gakuin University (JP)
Toho University (JP)
Kyushu University (JP)
Hirosaki University (JP)
Nagoya City University (JP)
Toyonaka Municipal Hospital (JP)
Kyushu University Hospital (JP)
Toneyama National Hospital (JP)
National Hospital Organization (JP)
Osaka University Hospital (JP)
Nagoya University (JP)
Nara Medical University (JP)
Kindai University (JP)
The University of Osaka (JP)

Publication Details

Journal: BMJ Open
Published: 2025-12-01
DOI: https://doi.org/10.1136/bmjopen-2025-112318
Primary Topic: Diabetes Treatment and Management
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Japan Agency for Medical Research and Development
Novo Nordisk

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study

Hiroyuki Kurakami, Takashi Tsuboi, Liqin Ge, Masaru Yokoe et al.

Dec 1, 2025

BMJ Open

Diabetes Treatment and Management

article

Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study

Hiroyuki Kurakami, Takashi Tsuboi, Liqin Ge, Masaru Yokoe, Hiroyuki Mochizuki, Osamu Kano, Kanako Asai, Dai Matsuse, Yasuyoshi Kimura, H. Kato, Shigeru Sakamoto, Toru Koda, Masahiko TOMIYAMA, Koji Iwasaki, Yoshitaka Nagai, Noriyuki Matsukawa

December 1, 2025article en

Abstract

No abstract available for this paper.

BMJ OpenVol. 15(12)

Osaka Gakuin University (JP), Toho University (JP), Kyushu University (JP), Hirosaki University (JP), Nagoya City University (JP), Toyonaka Municipal Hospital (JP), Kyushu University Hospital (JP), Toneyama National Hospital (JP), National Hospital Organization (JP), Osaka University Hospital (JP), Nagoya University (JP), Nara Medical University (JP), Kindai University (JP), The University of Osaka (JP)

Japan Agency for Medical Research and Development, Novo Nordisk

Good health and well-being

Openalex Percentile: Top 30%

Diabetes Treatment and Management

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study — Hiroyuki Kurakami, Takashi Tsuboi, et al. · BMJ Open (2025) | TGRS Research Map | TGRS